Corxel Pharmaceuticals Secures $287 Million in Series D1 Financing to Advance Oral GLP-1 RA CX11 and Cardiovascular-Metabolic Pipeline

● This Series D1 financing round involved participation from multiple global investment institutions focused on the healthcare sector, including RTW Investments, SR One Capital Management (SR One), TCG Crossover (TCGX), RA Capital Management, HBM Healthcare Investments, and SymBiosis.

● The proceeds will be used to support Phase 2 clinical trials of CX11, an oral small-molecule GLP-1 receptor agonist (RA), currently underway in the United States and planned for global expansion, and to advance other cardiometabolic programs.

January 21, 2026, New Jersey, USA—CORXEL (hereinafter referred to as “CORXEL”), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiovascular and metabolic diseases worldwide, today announced the successful completion of its Series D1 financing, raising up to $287 million. The proceeds from this round will be primarily used to advance the development of its pipeline candidate CX11. CX11 is an oral small-molecule GLP-1 receptor agonist (GLP-1 RA) with unique advantages. CORXEL is currently conducting a Phase 2 clinical trial in the United States to evaluate CX11 for the treatment of obesity and overweight, while its partner, Wentai Medicine, is conducting a Phase 3 clinical trial in China. In addition, the funds will be used to advance other cardiovascular and metabolic projects, including pipeline development for acute ischemic stroke and hypertension.

New investors in this financing round include S.R.One Ltd., TCGX, Adage Capital Management, RA Capital Management, HBM Healthcare Investments, SymBiosis, Invus, SilverArc Capital, and other investors. Existing investors RTW Investments and Hengdian Capital Venture Capital (Zhejiang) Co., Ltd. continued their participation, demonstrating their sustained confidence in the unique clinical advantages of CX11, CORXEL’s clinical development capabilities, and the company’s long-term strategy.

The funds raised in this round will be used for:

● Advance the development of the company’s core pipeline candidate, CX11, including the ongoing Phase 2 clinical trial in the United States for the treatment of obesity and overweight, as well as the planned global Phase 2 clinical trial for the treatment of type 2 diabetes, and support preparatory activities for the Phase 3 clinical trial of CX11;

● Advance the clinical development of other cardiovascular and metabolic projects, and

● Strengthen global operations and development capabilities to support the conduct of international multi-center clinical trials worldwide.

“This financing represents one of the most significant milestones for CORXEL since its inception, as it not only accelerates our development of globally leading therapies for cardiometabolic diseases but also propels CORXEL to new heights, ushering in a fresh trajectory of growth.”Ms. Mou Yanping, Executive Director and Chief Executive Officer of the Board of Directors of CORXEL, stated,“We sincerely thank both new and existing investors for their trust and support in CORXEL. We are more committed than ever to advancing CORXEL’s mission to become a globally leading biopharmaceutical company.”

“RTW is dedicated to driving the next generation of breakthroughs in science and medicine to help transform patients’ lives,”Roderick Wong, Managing Partner and Chief Investment Officer at RTW Investments, stated,"We believe that CORXEL’s clinical progress, rigorous execution capabilities, and experienced leadership team will lay the foundation for the company to achieve key milestones in the near term and create long-term sustainable value. We are delighted to support CORXEL’s growth into a leading biotechnology company in the field of cardiometabolic diseases."

With the completion of this round of financing, S.R.One Ltd., TCGX, and other designated investors will appoint three new representatives to join the Board of Directors of CORXEL.

CORXEL is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiovascular and metabolic diseases worldwide. The company has extensive experience and a strong track record in identifying, licensing, and developing high-quality clinical candidates targeting validated targets with well-defined mechanisms of action (MoA). CORXEL’s diversified clinical-stage pipeline has the potential to redefine standards of care by addressing key limitations of current therapies for various cardiovascular and metabolic conditions. The company is developing a curated portfolio of small-molecule compounds covering the cardiovascular and metabolic disease space, with core products including CX11, an oral GLP-1 receptor agonist for the treatment of obesity and overweight as well as type 2 diabetes; JX10, a novel thrombolytic agent with anti-inflammatory properties for the treatment of patients with acute ischemic stroke (AIS); and JX09, a highly selective aldosterone synthase inhibitor (ASI) for the treatment of hypertension. CORXEL also has other small-molecule programs targeting validated obesity targets under development.